Denmark is often described as a “DRG country”. That is technically true but strategically misleading. On the surface, the Danish DRG system looks familiar: national groupers, published tariffs, annual updates, …

Introduction: Why Netherlands Surgical Reimbursement Works Differently Securing Netherlands surgical reimbursement is unlike any other European market. The Dutch system links reimbursement directly to minimum-volume standards, hospital authorisation, and insurer …

German Hospital Reform 2025 German Hospital Reform 2025 marks a fundamental shift in how hospitals secure DRG eligibility, structure their service portfolios, and stabilise their finances. For more than two …

Pharmaceutical Reimbursement in Poland: A 2025 Deep Dive Poland’s pharmaceutical reimbursement system remains one of Europe’s most structured, evidence-driven, and economically disciplined models. For manufacturers, health-economics teams, and policy specialists, …

Introduction Why Reimbursement Analysis Fails to Give You an Accurate Picture of MedTech Funding In every DRG-based health system — whether Germany’s G-DRG, France’s GHS, the UK’s NHS Payment Scheme, …

This article reviews the most important biotech news this week, highlighting the breakthrough approval of Bayer’s non-hormonal menopause drug Lynkuet and the major clinical failure faced by Alector in frontotemporal …